Antidepressants: Past, present and future

European Journal of Pharmacology

Volumn 405, Issue 1-3, 2000, Pages 351-363

  Vetulani, Jerzy ^a   Nalepa, Irena ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Antidepressant; Intracellular signaling; Mechanism of action; Monoamine; Neuropeptide; Transcription factor

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR; CITALOPRAM; DOPAMINE; GLUTAMATE RECEPTOR; MOCLOBEMIDE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR ANTAGONIST; NEUROPEPTIDE Y; NEUROTRANSMITTER RECEPTOR; NORADRENALIN UPTAKE INHIBITOR; OXYTOCIN; PAROXETINE; PROTEIN KINASE; PROTIRELIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASOPRESSIN; VENLAFAXINE;

CONFERENCE PAPER; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG MECHANISM; GENE EXPRESSION; GENOME; HUMAN; HYPOTHESIS; MOOD; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION;

ANIMAL; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMAN; MOOD DISORDERS; NEUROPEPTIDES; NEUROTRANSMITTERS;

EID: 0034730476     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00565-3     Document Type: Conference Paper

References (163)

1. 2 receptor expression and dopamine release in the nucleus accumbens of the rat
2. Hormonal disturbances in depression
3. 2+ channel blockade with nifedipine
4. Aged rats are still responsive to the antidepressant and memory-improving effects of oxytocin
5. Oxytocin acts as an antidepressant in two animal models of depression
6. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors
7. Differential G protein measures in mononuclear leukocytes of patients with bipolar mood disorder are state dependent
8. Dynamics of ECT normalization of low G protein function and immunoreactivity in mononuclear leukocytes of patients with major depression
9. The involvement of guanine nucleotide binding proteins in the pathogenesis and treatment of affective disorders
10. The effects of seasons and light therapy on G protein levels in mononuclear leukocytes of patients with seasonal affective disorder
11. Substance P antagonists: the next breakthrough in treating depression?
12. Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus
13. Development of β adrenergic receptor subsensitivity by antidepressants
14. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?
15. Effect of zimelidine (H 102/09) in depressive patients
16. The noradrenergic cyclic AMP generating system in the limbic forebrain: pharmacological characterization in vitro and possible role of limbic noradrenergic mechanisms in the mode of action of antipsychotics
17. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study
18. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications
19. Down-regulation of beta adrenergic receptors following repeated injections of desmethylimipramine: permissive role of serotonergic axons
20. The effect of chronic treatment with antidepressant drugs on the corticosteroid receptor levels in the rat hippocampus
21. Norepinephrine in depressive reactions
22. Pharmacology of a new phthalane (Lu 10-171), with specific 5-HT uptake inhibiting properties
23. Biochemical aspects of depression
24. Long-term regulation of locus ceruleus sensitivity to corticotropin-releasing factor by swim stress
25. Fluoroepinephrines: specific agonists for the activation of alpha and beta adrenergic-sensitive cyclic AMP-generating system in rat slices
26. Cyclic AMP-generating systems: regional differences in activation by adrenergic receptors in rat brain
27. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study
28. Neuropeptides: animal behaviour and human psychopathology
29. Phylogeny of tachykinin receptor localization in the vertebrate central nervous system: apparent absence of neurokinin-2 and neurokinin-3 binding sites in the human brain
30. Novel therapeutic approaches beyond the serptonin receptor
31. Modulation of receptor-mediated cyclic AMP production in brain
32. A molecular and cellular theory of depression
33. A role for CREB in antidepressant activity
34. 2 dopamine receptors in the rat brain
35. The 'serotonin/norepinephrine link' beyond the beta adrenoceptor
36. Receptor regulation; evidence for a relationship between phospholipid metabolism and neurotransmitter receptor-mediated cAMP formation in brain
37. The effect of transcranial magnetic stimulation of rat brain on behavioral models of depression
38. Effect of chronic antidepressant treatment on transcription factor binding activity in rat hippocampus and frontal cortex
39. Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine (Lilly 110140)
40. Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial
41. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression
42. Nitric oxide synthase inhibitors have antidepressant-like properties in mice: 1. Acute treatments are active in forced swim test
43. Noradrenergic lesion antagonizes desipramine-induced adaptation of NMDA receptors
44. Antidepressant drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain
45. 'Crosstalk' a pivotal role for protein kinase C in modulating relationships between signal transduction pathways
46. Is an adaptation of NMDA receptors an obligatory step in antidepressant action?
47. Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171
48. Interactions between the hormone-sensitive cyclase system and the phosphoinositide-metabolizing pathway in human platelets
49. Role of serotonergic input in the regulation of the beta adrenergic receptor coupled adenylate cyclase system
50. Role of the dopaminergic system in depression
51. Phorbol esters enhance a neurotransmitter-stimulated cyclic AMP production in rat brain slices
52. Protein kinase C phosphorylates the inhibitory guanine-nucleotide-binding regulatory component and apparently suppresses its function in hormonal inhibition of adenylate cyclase
53. 3H]-acetylcholine in rat caudatoputamen
54. Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin
55. Hedonic valence, dopamine and motivation
56. Distinct mechanism for antidepressant activity by blockade of central substance P receptors
57. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil
58. 1-adrenergic receptor phosphorylation and receptor uncoupling from inositol phospholipid metabolism
59. Psychotherapeutic profile of a new psychoactive drug trazodone (AF-1161)
60. Signal transducing G proteins and antidepressant drugs: evidence for modulation of alpha subunit gene expression in rat brain
61. Neurotrophic factors: from molecule to man
62. Central effects following repeated treatment with antidepressant drugs
63. 2 receptors in the rat brain
64. 3 receptors in the rat brain
65. The influence of repeated treatment with imipramine, (+)- and (-)-oxaprotiline on behavioural effects of dopamine D-1 and D-2 agonists
66. The effects of combined treatment with MK-801 and antidepressant drugs in the forced swimming test in rats
67. Repeated treatment with antidepressant drugs potentiates the locomotor response to (+)-amphetamine
68. Antidepressants given repeatedly increase the behavioural effect of dopamine D-2 agonist
69. Desipramine given repeatedly enhances behavioural effects of dopamine and d-amphetamine injected into the nucleus accumbens
70. Beta-adrenoceptor-linked protein kinase A (PKA) activity in human fibroblasts from normal subjects and from patients with major depression
71. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness
72. The antidepressant effects of trazodone and inhibition of platelet serotonin reuptake
73. Antidepressant-like affects of CP-154,526, a selective CRF1 receptor antagonist
74. 2-adrenergic heteroceptors on serotonin terminals in the mechanism of action of antidepressant drugs
75. cAMP-dependent phosphorylation system after short and long-term administration of moclobemide
76. The effects of chlorpromazine and haloperidol on second messenger systems related to adrenergic receptors
77. The effect of psychotropic drugs on the interaction of protein kinase C with second messenger systems in the rat cerebral cortex
78. 1-adrenoceptor activity by protein kinase C
79. Modulation by mianserin pretreatment of the chronic electroconvulsive shock effects on the adrenergic system in the cerebral cortex of the rat
80. Lack of β-adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine
81. Beta down-regulation induced by repeated vasopressin treatment
82. Involvement of protein kinase C in the mechanisms of in vitro effects of imipramine on generation of second messengers by noradrenaline in the cerebral cortical slices of the rat
83. Different mechanisms of β-adrenoceptor downregulation by chronic imipramine and electroconvulsive treatment: possible role for protein kinase C
84. 1-and β-adrenoceptors in the rat cerebral cortex
85. Enhancement of the responsiveness of cortical adrenergic receptors by chronic administration of the 5-hydroxytryptamine uptake inhibitor citalopram.
86. The responsiveness of cerebral cortical adrenergic receptors after chronic administration of atypical antidepressant mianserin
87. Modulation of electroconvulsive treatment induced β-adrenergic down-regulation by previous chronic imipramine administration: the involvement of protein kinase C
88. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments
89. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus
90. Chronic electroconvulsive treatment increases the activity of nitric oxide synthase in the rat brain
91. 2+ antagonists effect an antidepressant-like adaptation of the NMDA receptor complex
92. Swim stress increases the potency of glycine at the N-methyl-D-aspartate receptor complex
93. The pharmacology of zimelidine: a 5-HT selective reuptake inhibitor
94. On the slowness of action of tricyclic antidepressant drugs
95. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression
96. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression
97. Adaptation of the N methyl D aspartate receptor complex following chronic antidepressant treatments
98. Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists
99. Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain
100. Electroconvulsive seizures increase levels of (EEP) in rat brain
101. Increased glucocorticoid receptor gene promoter activity after antidepressant treatment
102. Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression
103. Effects of fluvoxamine on the protein phosphorylation system associated with rat neuronal microtubules
104. cAMP binding proteins in the rat cerebral cortex after administration of selective 5-HT and NE reuptake blockers with antidepressant activity
105. The effect of prolonged imipramine and electroconvulsive shock treatment on calcium/calmodulin-dependent protein kinase II in the hippocampus of rat brain
106. 3H]clonidine binding to rat cortical membranes
107. Similar action of imipramine and arginine-vasopressin in the social interaction test
108. Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs
109. 2+/calmodulin-dependent protein kinase II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake
110. Evolution of monoamine hypotheses of depression
111. The effect of long-term treatment with antidepressant drugs on the hippocampal mineralocorticoid and glucocorticoid receptors in rats
112. Mania, depression and brain dopamine
113. Antidepressant-like properties of prepro-TRH 178-199: acute effects in the forced swim test
114. Reduced adenylyl cyclase immunolabeling and activity in postmortem temporal cortex of depressed suicide victims
115. 3 receptors in the rat brain differentiated by agonist and antagonist binding - an autoradiographic analysis
116. Strategies to optimize the antidepressant action of selective serotonin reuptake inhibitors
117. (Z)-dimethylamino-1-(4-bromophenyl)-1-(3-pyridyl) propene (h 102/09), a new selective inhibitor of the neuronal 5-hydroxytryptamine uptake
118. Pharmacological actions of the antidepressant venlafaxine beyond aminergic receptors
119. Fluoxetine increases steady-state levels of preproenkephalin mRNA in rat amygdala by a serotonin dependent mechanism
120. Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant
121. Antidepressants: beyond the synapse
122. The role of TRH and related peptides in the mechanism of action of ECT
123. The catecholamine hypothesis of affective disorders: a review of supporting evidence
124. Inhibition by antidepressant drugs of cyclic AMP response element binding protein/cyclic AMP response element directed gene transcription
125. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression
126. Cyclic AMP-dependent protein kinase in subtypes of major depression and normal volunteers
127. cAMP-dependent protein kinase activity in major depression
128. Oligodeoxynucleotides antisense to mRNA encoding protein kinase A, protein kinase C and β-adrenergic receptor kinase reveal distinctive cell-type specific roles in agonist-induced desensitization
129. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat
130. Second generation antidepressants
131. Antidepressants for the new millenium
132. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression
133. The substance P antagonist L-760,735 inhibits stress-induced NK(1) receptor internalisation in the basolateral amygdala
134. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats
135. Activators of protein kinase C act at a postreceptor site to amplify cyclic AMP production in rat pinealocytes
136. Adrenergic mechanisms in the central action of tricyclic antidepressants and substituted phenothiazines
137. Mode of action of antidepressant drugs
138. Localization of subspecies of protein kinase C in the mammalian central nervous system
139. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
140. Oxytocin as a possible mediator of SSRI-induced antidepressant effects
141. Complex action of antidepressant treatment on central adrenergic system: possible relevance to clinical effects
142. Current concepts of mechanisms of action of antidepressant treatments based on preclinical studies
143. Action of various antidepressant treatment reduces reactivity of noradrenergic cyclic AMP generating system in limbic forebrain
144. 3H]prazosin binding sites in the central nervous system of the rat
145. 3H prazosin binding sites in the rat
146. A possible common mechanism of action of antidepressant treatments. Reduction in the sensitivity of the noradrenergic cyclic AMP generating system in the rat limbic forebrain
147. Adaptive mechanisms in the norepinephrine-sensitive cyclic AMP generating system in the slices of the rat limbic forebrain
148. Dysbalance of neuronal second messenger function in the aetiology of affective disorders: a pathophysiological concept hypothesising defects beyond first messenger receptors
149. Electroconvulsive shocks increase the concentration of neocortical and hippocampal neuropeptide Y (NPY)-like immunoreactivity in the rat
150. Effects of neuropeptide Y (NPY) at the sympathetic neuroeffector junction. Can pre- and postjunctional receptors be distinguished?
151. Neuropeptide Y (NPY) in the area of the hypothalamic paraventricular nucleus activates the pituitary-adrenocortical axis in the rat
152. Cyclic AMP responsive element binding protein phosphorylation and DNA binding is decreased by chronic lithium but not valproate treatment of SH-SY5Y neuroblastoma cells
153. Differential effects of electroconvulsive shock on the glutamate receptor mRNAs for NR2A, NR2B and mGluR5b
154. Rapid down-regulation of beta-adrenergic receptors evoked by combined forced swimming test and CGP 37849-a competitive antagonist of NMDA receptors
155. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively
156. Increased sensitivity to dopaminergic agonists after repeated electroconvulsive shock (ECS) in rats
157. The mesolimbic dopamine system as a target for rapid antidepressant action
158. Expression of the enkephalin precursor gene in C6 rat glioma cells: regulation by beta-adrenergic agonists and glucocorticoids
159. Lithium activates the c-Jun NH2-terminal kinases in vitro and in the CNS in vivo
160. How long should pindolol be associated with paroxetine to improve the antidepressant response?
161. Deep magnetic brain stimulation - the end of psychiatric electroshock therapy?
162. Preliminary comparison of behavioral and biochemical effects of chronic transcranial magnetic stimulation and electroconvulsive shock in the rat